Home > Dermatology > AAD 2021 > Late-Breaking Abstracts > Novel easy-to-use foam formulation clears scalp psoriasis in one-third of patients

Novel easy-to-use foam formulation clears scalp psoriasis in one-third of patients

Presented By
Prof. Leon Kircik, Icahn School of Medicine at Mount Sinai Medical Center, USA
Conference
AAD VMX 2021
Roflumilast foam is an attractive novel topical treatment for scalp and body psoriasis with a fast onset of action and remarkable efficacy in a phase 2 study. “Almost 80% of our patients have scalp psoriasis; itching and flaking are some of the most burdensome symptoms of psoriasis,” said Prof. Leon Kircik (Icahn School of Medicine at Mount Sinai Medical Center, USA) [1]. These symptoms can cause social embarrassment and have a high impact on quality of life. Treatment of the scalp is difficult because the hair may limit the efficacy of creams and ointments [2]. Roflumilast is a potent, non-steroidal phosphodiesterase-4 inhibitor being investigated as a topical treatment for various dermatologic conditions. It is formulated in a moisturising foam that can be easily applied on the scalp and the body. In the current double-blind, randomised, placebo-controlled phase 2 study (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on